392 related articles for article (PubMed ID: 11593388)
1. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
Hoover RR; Gerlach MJ; Koh EY; Daley GQ
Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
[TBL] [Abstract][Full Text] [Related]
2. STAT5-Dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells.
de Groot RP; Raaijmakers JA; Lammers JW; Koenderman L
Mol Cell Biol Res Commun; 2000 May; 3(5):299-305. PubMed ID: 10964754
[TBL] [Abstract][Full Text] [Related]
3. Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line.
Rosa Santos SC; Dumon S; Mayeux P; Gisselbrecht S; Gouilleux F
Oncogene; 2000 Feb; 19(9):1164-72. PubMed ID: 10713704
[TBL] [Abstract][Full Text] [Related]
4. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway.
Santos SC; Lacronique V; Bouchaert I; Monni R; Bernard O; Gisselbrecht S; Gouilleux F
Oncogene; 2001 Apr; 20(17):2080-90. PubMed ID: 11360192
[TBL] [Abstract][Full Text] [Related]
5. Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation.
Nosaka T; Kitamura T
Exp Hematol; 2002 Jul; 30(7):697-702. PubMed ID: 12135666
[TBL] [Abstract][Full Text] [Related]
6. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
7. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway.
Cortez D; Stoica G; Pierce JH; Pendergast AM
Oncogene; 1996 Dec; 13(12):2589-94. PubMed ID: 9000132
[TBL] [Abstract][Full Text] [Related]
8. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line.
Dumon S; Santos SC; Debierre-Grockiego F; Gouilleux-Gruart V; Cocault L; Boucheron C; Mollat P; Gisselbrecht S; Gouilleux F
Oncogene; 1999 Jul; 18(29):4191-9. PubMed ID: 10435632
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
[TBL] [Abstract][Full Text] [Related]
10. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
Nieborowska-Skorska M; Slupianek A; Skorski T
Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
Ahmed M; Dusanter-Fourt I; Bernard M; Mayeux P; Hawley RG; Bennardo T; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Turhan AG
Oncogene; 1998 Jan; 16(4):489-96. PubMed ID: 9484838
[TBL] [Abstract][Full Text] [Related]
12. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation.
Kieslinger M; Woldman I; Moriggl R; Hofmann J; Marine JC; Ihle JN; Beug H; Decker T
Genes Dev; 2000 Jan; 14(2):232-44. PubMed ID: 10652277
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner.
Cambier N; Chopra R; Strasser A; Metcalf D; Elefanty AG
Oncogene; 1998 Jan; 16(3):335-48. PubMed ID: 9467959
[TBL] [Abstract][Full Text] [Related]
14. Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
Rahmani M; Reese E; Dai Y; Bauer C; Kramer LB; Huang M; Jove R; Dent P; Grant S
Mol Pharmacol; 2005 Apr; 67(4):1166-76. PubMed ID: 15625278
[TBL] [Abstract][Full Text] [Related]
15. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; GodÃnez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
16. STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells.
Nosaka T; Kawashima T; Misawa K; Ikuta K; Mui AL; Kitamura T
EMBO J; 1999 Sep; 18(17):4754-65. PubMed ID: 10469654
[TBL] [Abstract][Full Text] [Related]
17. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Wang Z; Sampath J; Fukuda S; Pelus LM
Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
[TBL] [Abstract][Full Text] [Related]
18. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Chai SK; Nichols GL; Rothman P
J Immunol; 1997 Nov; 159(10):4720-8. PubMed ID: 9366395
[TBL] [Abstract][Full Text] [Related]
19. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block.
Nishii K; Kabarowski JH; Gibbons DL; Griffiths SD; Titley I; Wiedemann LM; Greaves MF
Oncogene; 1996 Nov; 13(10):2225-34. PubMed ID: 8950990
[TBL] [Abstract][Full Text] [Related]
20. C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis.
Skorski T; Nieborowska-Skorska M; Szczylik C; Kanakaraj P; Perrotti D; Zon G; Gewirtz A; Perussia B; Calabretta B
Cancer Res; 1995 Jun; 55(11):2275-8. PubMed ID: 7757976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
